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Summary.-A micro-cytotoxicity assay was adapted for the detection of cell-depen-
dent antibodies (CDA). Using normal rat spleens as the source of effector cells such
CDA activity was readily demonstrable in allo-immune sera tested on cultured
sarcoma cells. The same technique was then used to examine for tumour specific
antibodies in the sera of Hooded rats bearing a " non-immunogenic " syngeneic
metastasizing sarcoma. During the early stages of tumour growth, at Days 7 and
14, tumour specific CDA cytotoxici1y was detectable at high titres. By Day 21,
however, this activity had completely disappeared from the serum. This cell-
dependent cytotoxicity was tumour specific in that it did not kill cells from an unre-
lated syngeneic sarcoma, and the activity was probably confined to immunoglobulin
G as detected by molecular weight separation techniques. Following tumour
amputation at Day 21, this type of specific antibody activity rapidly re-appeared in
the serum. The presence of tumour specific CDA showed an inverse correlation
with the presence of specific inhibitors of cell-mediated immunity in the same sera.
At no stage in tumour growth could complement-dependent cytotoxicity be detected
in tumour bearing rat sera.
It is concluded that cell-dependent cytotoxic activity is not associated with
conventional complement dependence, that this CDA type of assay is exquisitely
sensitive and is suitable for the detection of anti-TSTA antibodies in tumour bearing
rats.
The possible significance of CDA activity in syngeneic tumour immunity is
discussed briefly. The results suggest that the role of humoral immune mechan-
isms in host resistance to tumour growth needs re-appraisal.
RECENTLY the distinction between
humoral and cellular effector mechanisms
has become blurred. Non-immune lym-
phoid cells may be induced to lyse target
cells in vitro by the addition of specific
antibody (Moller, 1965). This pheno-
menon of the cell dependence of antibody
activity has been intensively investigated
and reviewed by Perlmann, Perlmann and
Wigzell (1972) and MacLennan (1972).
Cell-dependent antibody (CDA) activity
has been detected in both xenogeneic and
allogeneic antisera. Hersey and his col-
leagues (Hersey, Cullen and MacLennan,
1973) have demonstrated such CDA acti-
vity against HLA antigens in multiparous
sera and have indicated that additional
specificities, not detected by the conven-
tional complement-dependent lytic assay,
were revealed. Furthermore, CDA pheno-
mena are frequently detectable at ex-
tremely low concentrations of antibody.
Perlmann and his colleagues (Perlmann
et al., 1972) using xenogeneic antisera
against fowl erythrocytes have detected
lytic effects at titres of 1 in 109 and have
concluded that as few as 100 specific
immunoglobulin molecules are sufficient
to lyse an erythrocyte. The nature ofthe
co-operating effector cells is as yet unclear;
they are apparently plentiful in spleen,
peritoneal exudate and blood, but absentC. BASHAM AND G. A. CURRIE
from thoracic duct lymph. Earlier studies
(MacLennan, 1972) have implied that the
responsible cell is a lymphocyte and, as a
result, the antibody effect has become
known as lymphocyte-dependent anti-
body (LDA). Until the identity of this
cell is established beyond dispute it
would seem rational to employ the term
"cell-dependent antibody" (CDA).
The exquisite economy in the use of
antibody and the non-specific requirement
for effector cells make this CDA pheno-
menon an attractive mechanism, potenti-
ally relevant in tumour specific reactions.
The studies of Lamon and his col-
leagues (Lamon et al., 1973), which show
that the effector cells in tumour bearing
animals, capable of specifically lysing
tumour cells were not T lymphocytes,
could indicate a possible role for cell-
co-operating antibody. A form of serum-
cell co-operation has been described by
Pollack and her colleagues (Pollack et al.,
1972; Pollack, 1973) who showed that
normal lymphoid cells can be rendered
specifically cytotoxic by sera from mice
bearing a syngeneic tumour, and recently
Hellstrom, Hellstrom and Warner (1973)
have described a similar specific " arming "
of normal peripheral blood lymphoid
cells by the sera from a few cancer pati-
ents. While these studies have revealed
a serum factor which " arms " lymphoid
cells they did not demonstrate either the
presence of antibody or any affinity of
the active component for tumour cells.
Co-operation of tumour specific antibodies
with non-sensitized cells may constitute
a potent effector limb of the host's
immune reactions to tumour cells.
This communication describes experi-
ments designed to detect such cell-
dependent tumour specific antibodies in
rats bearing a syngeneic spontaneously
metastasizing sarcoma, and to examine
the influence oftumour growth and tumour
amputation on such antibody activity.
MATERIALS AND METHODS
Rats. The animals used for these experi-
ments were adult pure line Wistar and
Hooded rats. Each strain is genetically and
antigenically homogeneous as detected by
skin grafting, maintained free of specific
pathogens and the rats were used between
10 and 14 weeks of age.
Tumours.-The tumour used for these
studies (MC3) has been described in a previous
paper (Currie and Gage, 1973). It is a
" non-immunogenic" sarcoma which never-
theless evokes specific cell-mediated responses
in syngeneic Hooded tumour bearing male
rats. It grows rapidly and gives rise to
metastases in regional lymph nodes and
lungs. The HSN tumour, described in the
same paper, was employed as a control for
specificity. It is syngeneic in female Hooded
rats. Both tumours were implanted in the
right hind limb of Hooded rats of the appro-
priate sex by the intramuscular inoculation
of 0-2 ml of a mechanically prepated tumour
mince.
Sera.-Normal Hooded and Wistar rat
sera, MC3 tumour bearing sera at Days 7,
14 and 21, after inoculation, and HSN
tumour bearing sera at Days 7, 14 and 21
were obtained by percutaneous cardiac
puncture of ether-anaesthetized rats and
stored at -20°C until use. A Wistar anti-
hooded allo-antiserum was similarly obtained
after immunization of normal Wistar rats
with 2 x 107 hooded spleen cells on two
occasions at 14-day intervals. The sera
were obtained 14 days after the last immuni-
zation.
Spleen cells.-Normal spleens were re-
moved from Hooded or Wistar adult normal
rats, finely chopped and the subsequent
mince suspended in medium 199 and filtered
through surgical gauze. The cell suspensions
were washed three times in large volumes of
medium 199 and suspended in complete
medium. They were then admixed with the
test serum dilutions to give a final ratio of
nucleated effector cells to target cells of
50: 1, as described above. For assays of the
allo-antiserum Wistar spleen cells were used,
but for the syngeneic sera cells from Hooded
spleens were employed.
Target cells. Cells from both MC3 and
HSN tumours were prepared and grown in
RPMI 1.640 plus 10% foetal bovine serum and
10 mmol HEPES as previously described
(Currie and Gage, 1973).
Microcytotoxicity assay. Microplates
(Falcon 3034) were inoculated with MNC3 or
HSN target cells which were allowed to
190DEVELOPMENT OF SPECIFIC CELL-DEPENDENT ANTIBODY
attachovernight at37°C asdescribed byCurrie
and Gage (1973). The test sera were assayed
for both complement-dependent cytotoxic
activity and cell-dependent cytotoxicity. For
the complement-dependent assay the super-
natant medium was aspirated from the target
cells and replaced by serial dilutions of test
and control sera diluted in complete medium.
The plates were then incubated at room
temperature for 1 h. The sera were removed
and replaced by 1: 100 unabsorbed weanling
New Zealand rabbit serum. The serum was
obtained by heart puncture from mweanling
rabbits, and stored under liquid nitrogen
until use. It is, in this test system, a potent
complement source with minimal natural
cytotoxic activity for rat cells. After addi-
tion of the complement the mieroplates w%ere
inverted and incubated at 37°C for 18 h.
The plates were then rinsed with phosphate
buffered saline, fixed in methanol and stained
with Giemsa. The number of cells remaining
in each well was then counted by light
microscopy. The results are expressed as
00 cytotoxicity, each point representing at
least 10 replicate wells.
For cell-dependent antibody assays the
supernatant medium was replaced by the
test sera in serial dilution admixed with
spleen cells. The final ratio of nucleated
spleen cells to target cells was 50: 1 in all
cases. Preliminary studies had shown this
to be the optimum concentration for evoking
CDA effects without causing non-specific cell
detachment or lysis. The microplates w,ere
incubated at 37°C for 24 h, then inverted for
1 h, rinsed, fixed and stained. The cells in
each well were counted and the means +1
standard deviation calculated. A cytotoxic
index was calculated thus:
AMean No. of cells in control wells-
Mean No. of cells in test wells 10°
Mean No. of cells in control wells x 10
Each mean in this assay represents the
average count in eight wells.
Serum fractionation.-Aliquots of MC3
tumour bearing sera, Days 7, 14 and 21
were fractionated on a Biogel A-0*5 m
column in glycine-tris buffer (pH 8 0). The
fractions collected were pooled into three
batches from each serum and then concen-
trated in an Amicon ultrafiltration cell using
a PMIO membrane and then dialysed against
phosphate-buffered saline. Fractions cor-
responding to the following approximate size
ranges were taken. Fraction I contained all
those molecules above 3 x 105 daltons,
Fraction II containing those molecules
between 3 x 105 and 105, and Fraction III
containing moieties below 105 daltons. The
column had been calibrated with blue
dextran, albumin and cytochrome c.
RESULTS
(1omplement-dependent and cell-dependent
lytic activity in alloimmune serum
As a test for the validity of the
microassay we started by attempting to
detect CDA activity in Wistar anti-
Hooded alloimmune serum and compared
it with complement-dependent cytotoxi-
city. Normal Wistar serum admixed
with Wistar spleen cells was not cytotoxic
to HSN cells at any titre, whereas the
immune serum caused significant lysis of
these Hooded sarcoma cells at titres
much higher than that obtained with the
complement-dependent lytic assay (Fig.
1). Prozone effects were often detectable
in this CDA activity.
By incubating the allo-antiserum with
either the target cells or the spleen cells
for I h it was found that the CDA activity
was detectable only after pre-incubation
with target cells and not with lympho-
cytes. However, this affinity for target
cells could only be demonstrated when the
serum was pre-incubated in the micro-
plates at 4°C. At 37°C affinity for target
cells could not be detected, presumably
due to phenomena such as the shedding
of immune complexes.
Complement-dependent cytotoxic activity in
syngeneic tumour bearing sera
At no stage of tumour growth could
complement-dependent lysis of MC3 cells
be detected in tumour bearing sera, or
normal Hooded sera, although such target
cells are readily killed by allo-antibody
an(I complement.
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FIG. 1. A comparison of the complement-dependent and cell-dependent cytotoxic activity of a
Wistar anti-Hooded antiserum tested on HSN (Hooded) sarcoma cells: 0-0 tested with rabbit
complement; 0 ----0 tested with Wistar normal spleen cells.
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FIG. 2.-Cell-dependent cytotoxic activity of MC3 tumour bearing sera during tumour growth and
following tumour amputation (Reciprocal titre of peak activity): **- tested on MC3 cells;
0 - -- -0 tested on HSN cells.
Tumour specific CDA in tumour bearing
sera
Sera from MC3 tumour bearing rats at
Days 7, 14 and 21 were assayed for CDA
activity on MC3 and HSN target cells, as
was normal Hooded rat serum. This
normal serum showed no cytotoxic acti-
vity, whereas tumour bearing (MC3) sera
at Days 7 and 14 were cytotoxic to MC3
cells at high titre. The same sera were
without cytotoxic effects on HSN cells.
MC3 tumour bearing serum at Day 21
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TABLE I. Cell-dependent Cytotoxic Activity of MC3 Tumour Bearing Sera at Days 7, 14
and 21 Tested on MC3 and HSN Cells
Serum anld titre
Day 7 Tumour bearing
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
Day 7 Tumour bearing
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
Day 14 T'umour bearing
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
Daly 14 Tumour bearing
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nril
I)ay 21 T'umour bearing
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
Day 21 Tumour bearing
5 x 10-1
Target cells
MC3
HSN
MC3
HSN
MC3
HSN
5 x 10-2
S x 10-3
5 x 10-4
5 x 10-5
Nil
Effector cells
Normal hooded
spleen cells
Normal hooded
spleen cells
Normal hooded
spleen cells
Normal hooded
spleen cells
,.
Normal Hooded
spleen cells
Normal Hooded
spleen cells
Mean No. of cells
left per well
±1 SD
904- 7-8
83±9 4
80±9-6
62±11
52±7-4
88±9-2
99±16-2
83-4-10-6
864-11-3
101±8-4
91±14- 1
94±11 -9
95±9
80±6-9
84±6-4
64±6-7
65±7 - 1
107± 13
86±9- 7
91±13-5
89911-6
92±12-2
83±11 -8
88±9-4
97±9- 1
98±8 - 6
85±9-8
96±9-2
93± 13
91±6
97117 -7
91±6-6
91±12-2
102± 9 - 4
98±8-8
92±9-6
Normal Hooded
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
MIC3 Normal Hooded
spleen cells
o/o
Cytotoxicity
0
5-7
9*1
29-6
39-8
0
11-7
8-5
0
3-6
11 -2
25-2
21 -5
40-2
39-3
2-3
0
0
0
5-7
0
0
6-6
0
0
1*1
1-1
0
0
95 ±8 - 2
97±9 0
97±7 2
94±6-8
93 ±6 - 7
93±7-1
0
0
0
0
0
0
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TABLE I-(continued)
Serum andl titre
Normral Hoodedl
5 x 10-1
5 x 10-2
5 x 10-3
5 x 10-4
5 x 10-5
Nil
Target cells
HISN
Effector cells
Normal Hoodel
spleen cells
Mtean No. of cells
left pet well
4I SD
86-8-4
84112* 7
85-1-5.4
88±55
87± 14-9
84 - 7.4
was, however, totally without tumour
specific CDA activity (Table I and Fig. 2).
These tumour bearing sera were then
fractionated as described and each frac-
tion assayed for tumour specific CDA
activity on MC3 cells. As Table III
indicates, the cytolytic activity in Days
7 and 14 sera was confined to Fraction II.
The feeble activity present in Fraction III
is presumably due to overlap of IgG. All
three fractions of Day 21 serum were
without activity. The tumour specific
CDA activity in earlier tumour bearing
0
Lu
I--
LuJ
a.
sera is therefore in the same molecular
weight range as IgG.
Effect of tumour amputation
At 21 days of tumour growth MC3
tumour bearing rats were ether-anaesthe-
tized and their tumour bearing limbs
surgically amputated. Sera from these
rats were collected at 2 and 6 days
subsequently and assayed for CDA acti-
vity against MC3 and HSN cells. Table II
and Fig. 2 demonstrate that such tumour
amputation is associated with the prompt
z
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I
z
u
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0
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FIG. 3.-Inverse correlation between tumour specific cell-clependent cytotoxicity and the presence
of a specific inhibitor of cell mediated cytotoxicity: 0 0 tumour specific cell-dependent cyto-
toxicity; 0 ---- -specific seruim inhibitoiy activity.
C(ytotoxicity
0
0
0
0
0
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re-appearance of tumour specific CDA
activity in the serum.
Serum inhibition of cell-mediated cytotoxi-
city and its correlation with CDA activity
Previously Currie and Gage (1973)
have examined Days 7, 14 and 21 sera
from MC3 tumour l earing Hooded rats
and demonstrated the evolution of a
specific inhibitor of lymph node cell
cytotoxicity in such sera with tumour
progression. The same sera were assayed
for tumour specific CDA activity and the
results are shown in Fig. 3. As this
diagram indicates the appearance of this
inhibitory activity is associated with the
disappearance of the antibody.
DISCUSSION
In the sera of rats bearing a syngeneic
sarcoma anti-TSTA antibodies can be
detected which co-operate with normal
spleen cells to exert their cytotoxic
effects. Other conventional assays such
as complement-dependent cytotoxicity
fail to detect such antibodies.
The antibodies responsible for this
co-operative cytotoxic effect do not seem
TABLE II. Effect of Tumour Amputation at Day 21 on Tumour Specific
CDA Activity
Serumrn aii(I titi e
I)ay 2 Post-e np.
5 X 10-1
5 x 10- 2
5 x 10- 3
5 x 10 4
5 x 10-5
5 x 10 -f
Nil
1)cai 2 Post-tmp.
5 x 10-1
5 x 10 2
5 X 10 3
5 x 10-4
5 X 10-)
5 X 10-6
Nil
Target cells
MC3
HSN
I)ay ( 1 l mp.
F. / I 3IC3
o X 10-2
5 x 10-3
5 X 10-4
5 x 1O-5
5 x 10-t;
Nil
Effector cells
Normal Hooded
spleen cells
,.
,,
,,
,,
,,
Normal Hoo(ledl
spleen cells
,,
Normal Hoo(le(d
spleen cells
,,
Mean No. of cells
left per w-ell
1ISD
61 +-2 9
49±5 - 6
53 i7 6
54±6-7
53±65- 5
6017 - 1
69--30
96-'- 1 1* 1
105± 12
119+- 7 8
116±17 0
98 11-5
104±10 5
102±13 5
78±8
81+1 4
76±8 3
64+8 .5
59±4 8
56±7 2
83+7 2
l)oy 6 Post-"nep.
S X 10-1
5 x 10-2
5 x 10-3
S x 10-4
5 x 10-5
S x 10 6
Nil
HSN Normal Hoo(le(l
spleen cells
,,9
,,3
,,
,,
I..
,,1
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11-6
29-0
23-2
21 -7
23-2
13:-(0
5.9
0
0
3-9
0
6
2 4
8 4
22 9
28 9
32 5
69--3-6
76±8 6
81 +11 3
77±8 6
78±10 4
82-4-10-4
73±5.9
5) 5
0
0
0
0
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TABLE III. (1ell-dependent Cytotoxicity in Fractionated MC3 Tumour Bearing
Sera
Serum and fractiols
'Normal hoodedt serum
Fraction I
Fraction II
Fraction III
MC3-Tumour-bearing
Day 7
Fraction I
Fraction II
Fraction III
MIC3-Tumour-bearing
Day 14
Fraction I
Fraction II
Fraction III
MNC3-Tumour-bearing
Day 21
Fraction I
Fraction II
Fraction III
to constitute a specialized sub-class of
antibody molecule. They are IgG anti-
bodies which in allogeneic and xenogeneic
antisera are responsible for other effects
apart from CDA cytotoxicity (MacLen-
nan, 1972). In tumour bearing sera other
assay systems are not sensitive enough to
detect anti-tumour antibodies, but there
is no reason to suspect that CDA is in
any sense a special type of antibody.
However, the presence of tumour specific
CDA in tumour bearing serum would
rule out any blocking role for antibodies
in tumour bearing animals: if antibodies
can kill tumour cells in the presence of
unsensitized effector cells it is difficult
to see how they can be held responsible
for blocking the cytotoxic effects of sensi-
tized cells.
The nature of the co-operating effector
cell remains a topic for speculative contro-
versy. Its presence in peripheral blood
lymphocyte" preparations, absence
from thoracic duct lymph, presence of
Fc receptors and its abundance in spleen
and peritoneal exudate tend to incriminate
cells of monocyte-macrophage lineage, as
indicated by Greenberg et al. (1973).
00 Cytotoxicity
Tested on Teste(l oIi
MC3 HSN
0
0
2 I
1(o
42 6
4 8
51 4
12 6
44 8
7 6
49 9
14:3
4. 1
0
0
0)
0
4 0
2 7
(
1 2
0
0
:3 9
2 0
4 7
1 *3
2 1
1 8
Studies of the presence, nature and
evolution of effector cells in MC3 tumour
bearing rats are in progress.
The mode of co-operation between cells
and antibody which leads to target cell
lysis is unknown. One could, of course,
suggest that the effector cells are merely
a source of complement produced locally
at the site ofantibody binding. However,
the addition of carrageenan, a potent
complement inhibitor to CDA lytic sys-
tems, does not inhibit cytotoxicity (Yust
et al., 1973). Furthermore, the addition
of exogenous complement to our assays
of tumour bearing sera evoked no detect-
able target cell lysis. The addition of the
same complement source to an allogeneic
antiserum assay led to lysis of MC3 and
HSN target cells, although at titres
substantially below those at which the
CDA effect occurs with the same serum.
It seems unlikely that such a complement
effect can be incriminated in the CDA
cytotoxicity.
With increasing tumour growth the
CDA activity disappears from the serum,
as do specifically cytotoxic cells in the
regional lymph nodes in the same model
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system (Currie and Gage, 1973). Following
amputation of the tumour bearing limb
at Day 21 the antibodies rapidly re-
appear in the circulation. This finding
suggests that the presence of a large
growing tumour in some way suppresses
or absorbs out any circulating anti-TSTA
antibodies. The studies of Thomson,
Steele and Alexander (1973) rule out the
latter, and suggest that the release of
soluble cell-surface antigenic determinants
by complexing with the antibodies may
be responsible for clearing them from the
circulation. This is further supported
by our recent observation that the cells
of the MC3 sarcoma when in tissue culture
spontaneously shed soluble TSTA deter-
minants at a high rate (Currie and Alex-
ander, 1974). Thus, the evolution of
humoral immunity in the tumour bearing
animal described above may well be related
to the spontaneous shedding of soluble
antigen. With increasing tumour growth
the antibodies would eventually be over-
whelmed until a condition of antigen
excess occurs throughout the extracellular
fluid. The gradual disappearance of cir-
culating antibody leads to speculation
about its possible in vivo significance. As
suggested by the work of Proctor et al.
(1973) circulating humoral factors may be
responsible for the inhibition of pulmon-
ary metastases. Currie and Sime (1973)
have also shown that tumour specific
antibodies inhibit the motility of tumour
cells and suggested that they may conse-
quently inhibit the in vivo dissemination
of cells, thereby limiting invasiveness and
metastases.
The unique properties of this mode of
action of specific antibody which make it
such an attractive concept are its require-
ment for unsensitized effector cells and its
activity at very low concentrations. The
presence of tumour specific antibodies
which can co-operate with lymphoid cells
to kill target tumour cells in the serum of
tumour bearing animals would suggest
that humoral mechanisms may play a role
in host resistance to tumour growth. At
present it is difficult to ascribe such an
important role to this mechanism. As
MacLennan (1972) has emphasized, cell-
dependent antibody-mediated target cell
destruction can be inhibited or blocked
in many ways. Unrelated immune com-
plexes, free antigen or even immuno-
globulin all readily block CDA effects.
Furthermore, the effector cells are absent
from lymph and scarce in lymph nodes.
Lymph nodes, of course, constitute an
important site of host defence. The
presence of effector cells in peripheral
blood, spleen and peritoneal cavity could,
nevertheless, provide a potent systemic
effector mechanism in the peripheral
extracellular fluid responsible for the
inhibition of metastatic disease. The
potential significance of CDA in tumour
immunity and host resistance must re-
main a subject for speculation. This mode
of action of anti-TSTA antibodies may,
of course, represent an artificial in vitro
effect with little direct relevance to the
intact organism. Should this prove to be
the case, however, it still represents an
extremely potent assay system for the
detection of anti-tumour antibodies.
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